| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Vascular contraction and cancer cells; Przewaquinone A is a lipophilic diterpene quinone that induces a potent inhibitory action on vascular contraction. It also exhibits inhibitory activity against cancer cells, including A549, HCT15, and SK-OV-3. The compound's mechanism of action may involve the modulation of signaling pathways that regulate smooth muscle contraction and cancer cell proliferation. It is a natural product with potential therapeutic applications.
|
|---|---|
| ln Vitro |
In vitro, Przewaquinone A exhibits inhibitory activity against cancer cell lines A549, HCT15, and SK-OV-3. It inhibits vasoconstriction in isolated blood vessels. The compound is used to study the mechanisms of vascular smooth muscle contraction and cancer cell proliferation. It is typically dissolved in DMSO for in vitro assays. Its effects on cell viability and contraction are measured using standard assays.
|
| ln Vivo |
In vivo studies on Przewaquinone A are limited. The compound has shown inhibitory activity against cancer cells in vitro and vasodilatory effects in isolated tissues. However, detailed in vivo efficacy and pharmacokinetic data are not extensively documented. The compound is primarily used as a research tool for studying vascular biology and cancer. Further studies are needed to evaluate its in vivo activity.
|
| Enzyme Assay |
In vitro, cancer cell lines (e.g., A549, HCT15, SK-OV-3) are treated with Przewaquinone A at various concentrations, and cell viability is measured using standard assays such as MTT or CellTiter-Glo. The compound's effects on cell proliferation and apoptosis are assessed. For vascular studies, isolated blood vessels are treated with the compound, and isometric tension is measured to assess vasoconstriction inhibition. The compound is typically dissolved in DMSO.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for Przewaquinone A are not well-documented in the available literature. The compound is primarily used as a research tool for in vitro studies. Researchers using this compound for in vivo studies would need to establish appropriate dosing and administration routes based on the specific research objectives. The compound is for research use only and not for human therapeutic use.
|
| ADME/Pharmacokinetics |
Przewaquinone A has a molecular weight of 310.34 and the chemical formula C₁₉H₁₈O₄. It is a lipophilic diterpene quinone. The compound is soluble in organic solvents such as DMSO. It should be stored at 2-8°C, and it remains stable for up to 24 months when stored as directed. The compound is for research use only and not for human therapeutic use.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Przewaquinone A are not extensively documented. As a natural product with anticancer activity, it may have cytotoxic effects on cancer cells. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions, including the use of personal protective equipment. The compound should be stored in a sealed container in a cool, dry place away from incompatible materials.
|
| References | |
| Additional Infomation |
According to reports, salvia miltiorrhiza, salvia miltiorrhiza var. cristatum, and other organisms with available data contain propaquinone A.
Przewaquinone A is a lipophilic diterpene quinone isolated from Salvia przewalskii. It effectively inhibits vasoconstriction. It also exhibits inhibitory activity against cancer cells A549, HCT15, and SK-OV-3. It is a natural product with potential therapeutic applications. It is supplied as a solid and should be stored at 2-8°C. It is for research use only. |
| Molecular Formula |
C19H18O4
|
|---|---|
| Molecular Weight |
310.34382
|
| Exact Mass |
310.12
|
| CAS # |
76843-23-7
|
| PubChem CID |
619402
|
| Appearance |
Orange to reddish brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
430.4±40.0 °C at 760 mmHg
|
| Melting Point |
171-173℃
|
| Flash Point |
214.1±27.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.610
|
| LogP |
3.83
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
526
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CEHVTERMWMYLCP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18O4/c1-19(2)7-3-4-11-13(19)6-5-12-15(11)17(22)16(21)14-10(8-20)9-23-18(12)14/h5-6,9,20H,3-4,7-8H2,1-2H3
|
| Chemical Name |
1-(hydroxymethyl)-6,6-dimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2223 mL | 16.1114 mL | 32.2227 mL | |
| 5 mM | 0.6445 mL | 3.2223 mL | 6.4445 mL | |
| 10 mM | 0.3222 mL | 1.6111 mL | 3.2223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
